Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in RLAY.

← Back to Free Index

RLAY

Analysis as of: 2026-08-14

Relay Therapeutics, Inc.

Clinical-stage biotechnology company using its Dynamo discovery engine to develop small-molecule precision medicines for cancer and genetic disease.

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Focused franchise upside, still a one-asset bet

The setup offers meaningful upside if its lead PI3Kα program converts strong early data into approval and label expansion. The opportunity is real, but most of the economic story still rides on one molecule family.

Analysis

Thesis

Relay can plausibly grow into an approved precision-medicine franchise by 2031 if zovegalisib wins second-line breast cancer, keeps a credible first-line path alive, and opens a vascular-anomalies niche; Dynamo adds option value, but this is still a lead-asset equity story rather than a pure AI-platform rerating.

Last Economy Alignment

AI improves molecule design and portfolio triage, but value is captured through owned drug rights and FDA approval, not software pricing.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.5x (from 5 most recent analyses)

Reasoning

This is a focused-franchise case: if the lead molecule becomes a differentiated breast-cancer drug, adds a chronic rare-disease niche and proves the discovery engine can repeatedly matter, the company can rerate from science promise to commercial oncology value. The upside is meaningful, but concentration in one asset family keeps the setup below classic 10x biotech outcomes.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The core risk is not cash survival but proof conversion. Relay has enough capital and a credible discovery engine, yet most enterprise value still depends on zovegalisib delivering durable Phase 3 efficacy, acceptable chronic safety, workable companion-diagnostic execution and a clean regulatory path into sizable labels. If that chain breaks, both franchise value and platform credibility compress together.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

August 6, 2026 second-quarter 10-Q and 8-K refreshed the balance-sheet and share-count baseline after the May equity raise.
No new efficacy readout appeared in the last 7-10 days, so the thesis is still waiting on the next zovegalisib clinical disclosure.
Recent August ownership filings look technical rather than thesis-changing.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.35

They use AI plus proprietary wet-lab data to make better drug guesses, and every experiment can improve the next one. But they only really get paid if those molecules survive trials and regulators, so biology and FDA gates still matter more than compute.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$25.17

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research